Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Cantor Fitzgerald reaffirmed an ...

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Zai Lab (NASDAQ:ZLAB) despite recent market pressures. Trading at $24.32, Zai Lab stock has experienced significant downward ...

Cantor Fitzgerald doubled down on its bearish stance toward stocks on Monday, reaffirming its negative outlook with the statement, “we continue to be bearish on equities” in an investor note ...

Cantor Fitzgerald upgraded Tesla (TSLA, Financials) to Overweight from Neutral, citing a buying opportunity following the recent sell-off, the firm announced after a site visit to Tesla's ...

Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Bradmer Pharmaceuticals in a note issued to ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Tesla stock (NASDAQ:TSLA), the $770 billion market cap electric vehicle manufacturer, emphasizing its strategic focus on domestic ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating.Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory and AI data centers in Austin. The firm moved Tesla (NASDAQ ...

Tuesday - Shares of Microsoft Corporation (NASDAQ:MSFT), the $2.66 trillion tech giant with an impressive 69.41% gross profit margin, are in focus after Cantor Fitzgerald reiterated an Overweight ...

On Friday, Cantor Fitzgerald analysts maintained a Neutral rating and a $40.00 price target on Acadia Healthcare (NASDAQ: NASDAQ:ACHC), which currently trades at $28.38. According to InvestingPro data ...